Registr.No. 86681079 CoC Amsterdam

## **Balance Sheet as at 31 December 2024**

(Before appropriation of results and expressed in euros)

	Notes	31 December 2024 EUR	31 December 2023 EUR
FIXED ASSETS			
Financial fixed assets			
Long-term loans Securities	1 2	363.742 389.970	410.000 389.995
TOTAL FIXED ASSETS		753.712	799.995
CURRENT ASSETS			
Securities	2	304.937	304.333
Cash Other current assets	3	224.702 4.737	185.424
TOTAL CURRENT ASSETS		534.376	489.757
TOTAL ASSETS		1.288.088	1.289.752
OWN FUNDS			
Other reserves		1.289.752	739.288
Result for the period		(1.664)	550.464
		1.288.088	1.289,752

Registr.No. 86681079 CoC Amsterdam

# Profit and Loss for the period 01.01.2024 – 31.12.2024

(Expressed in euros)

	Notes	01/01/2024 - 31/12/2024	01/01/2023 - 31/12/2023
INCOME Donations received Donations paid	4	589.517 (540.000) <b>49.517</b>	590.710 - 590.710
OPERATING EXPENSES			
General and administrative expenses	5	(82.097)	(65.698)
TOTAL OPERATING EXPENSES		(82.097)	(65.698)
FINANCIAL INCOME / (EXPENSES) Interest income/(expenses) and similar income / (expenses)	6	30.916	25.452
TOTAL FINANCIAL INCOME / (EXPENSES)		30.916	25.452
NET RESULT		(1.664)	550.464

Registr.No. 86681079 CoC Amsterdam

#### Notes to the Financial statements 2024

#### General

Stichting Alivia International Foundation ("the Foundation") was incorporated on 10 June 2022 under the laws of the Netherlands. The Foundation has its statutory seat in Amsterdam and its business seat at Kabelweg 57, 1014 BA Amsterdam.

The purpose of the Foundation is to fight cancer. The Foundation acts to ensure equal access to the best cancer care for everyone, everywhere; defends the dignity of cancer patients and provide tools that enable them to make informed health decisions; undertakes its actions across borders.

The Foundation doesn't aim to make a profit.

Foundation's assets stand at sufficient level to compensate / cover ordinary Foundation's expenditures. The Foundation's resources consist of contributions by Alivia National Organizations (ANOs) – non-profit organizations registered in other countries and operating under the Alivia brand; gifts, donations, grants and bequests; interest and financial gains; third party contributions; subsidies; income from investment; benefits arising from any other source and other income.

These financial statements cover the period from 1 January 2024 till 31 December 2024.

## **Summary of principal accounting policies**

The financial statements have been prepared in accordance with the provisions of EU Directives as implemented in Part 9, Book 2 of the Netherlands Civil Code.

The Annual report has been prepared on a going concern basis.

These financial statements are presented in euros (EUR), which is the Foundation's functional currency. Transactions in foreign currency during the period in review are included in the annual accounts at the settlement rate.

Purchased bonds are measured at amortised cost.

Unless mentioned otherwise all other assets and liabilities are stated at historical (acquisition) prices.

Receivables, payables and liabilities in foreign currency are converted at the rate of the balance sheet date, except in so far as the exchange rate risk is covered. In those cases, valuation takes place at the agreed forward rates.

Exchange rate differences resulting from this conversion are included in the profit and loss account. The exchange rate used as at December 31, 2024 is:

PLN/EUR = 4,275

The "accrual concept" has been applied; meaning that items are accounted for in the period in which they were earned/incurred, regardless of the moment of receipt or payment.

The Foundation is not liable to pay corporate tax.

Registr.No. 86681079 CoC Amsterdam

## Notes to the Financial statements 2024

## 1. Long-term loans

Four loan agreements were made between the Foundation and Alivia Fundacion Oncologica (Spain) for the total amount of EUR 510.000:

Date	Loan amount	Debt relief	Maturity date
21.10.2022	100.000,00	(100.000)	31.12.2026
14.12.2022	50.000,00	(50.000)	31.12.2027
25.01.2023	260.000,00	(160.000)	31.12.2027
02.01.2024	100.000,00	-	31.07.2026

The interest rate for all loans is settled to 0% per year.

According to the Debt relief agreement between Foundation and Alivia Fundacion Oncologica (Spain) dated 23.12.2024 the total debt relief amount equals EUR 310.000.

#### 2. Securities

On July 24<sup>th</sup>, 2023 the Foundation bought 16.420 bonds with a nominal value of 100 PLN each. These bonds have a maturity date of July 24<sup>th</sup>, 2027. The annual interest rate is 7% for the first interest period.

On August 2<sup>nd</sup>, 2023 the Foundation purchased Netherlands government bonds in the amount of EUR 300.000. These bonds have a maturity date of July 15<sup>th</sup> 2024 and bear an interest rate of 3,34%.

On August 19<sup>th</sup>, 2024 the Foundation purchased Netherlands government bonds in the amount of EUR 304.937. These bonds have a maturity date of January 20<sup>th</sup> 2025 and bear an interest rate of 2,71%.

#### 3. Cash

The Foundation maintains its bank account, denominated in EUR, USD and PLN, with Alior Bank (Poland). The bank balances are available on demand.

#### 4. Income from donations

In 2024 the Foundation received EUR 589.517 according to the Donation agreements made and entered by and between Alivia – Fundacja Onkologiczna (Poland) and Stichting Alivia International Foundation.

Registr.No. 86681079 CoC Amsterdam

#### Notes to the Financial statements 2024

# 5. General and administrative expenses

General and administrative expenses in the amount to EUR 82.097 are comprised of administration expenses, consultancy fees and bank charges for the period from 1 January 2024 till 31 December 2024.

## 6. Interest income / (expenses) and similar income / (expenses)

Interest income / (expenses) and similar income / (expenses) consist as follows:

	<b>31 December 2024</b>
Interest income on bonds	19.911
Exchange rate difference	11.005
	30.916

#### Staff

During the reporting period, the Foundation had no employee.

#### **Board members**

The Foundation had one board member and three supervisory board members during the reporting period. The board members did not receive any remuneration for the duties of the board members.

Place: Date: 2025

Signed by:

Lata Polinska

Ms. Agata Izabela Polińska

Board member

DocuSigned by:

E383D12T348C4F4...

Mr. Robert Bron

Supervisory board member

Ms. Barbara Anna Dobrowolska Supervisory board member

—Docusigned by: Pawel Urawski

Dollow.

Mr. Pawel Teodor Urawski Supervisory board member

Registr.No. 86681079 CoC Amsterdam

# **Table of Contents**

	<u>Page</u>
Financial Statements	
1. Balance Sheet as at 31 December 2024	1
2. Profit and Loss account for the period ended 31 December 2024	2
3. Notes to the financial statements 2024	3 - 5

Registr.No. 86681079 CoC Amsterdam

# **Stichting Alivia International Foundation**

Amsterdam, the Netherlands

**ANNUAL REPORT** 

for the period ended 31 December 2024